Clinical trials: High-risk Smoldering Multiple Myeloma
Smoldering Plasma Cell Myeloma
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients.
- Trial name
- NCT04776395
- Testing
- Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Emory University
High Risk Smoldering Multiple Myeloma (HR-SMM)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of…
- Trial name
- LINKER-SMM2 (NCT07393282)
- Testing
- Linvoseltamab, Daratumumab
- Where
- 27 sites in United States, Japan and 3 more
- Volunteers
- 270 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Smoldering Multiple Myeloma
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.
- Trial name
- NCT05767359
- Testing
- Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma.
- Conditions
- High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT05469893
- Testing
- Teclistamab, Lenalidomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Irene Ghobrial, MD
Smoldering Plasma Cell Myeloma
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT03952832
- Testing
- Leflunomide, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- City of Hope Medical Center
High Risk Smoldering Multiple Myeloma
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.
- Trial name
- NCT02943473
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Smoldering Multiple Myeloma
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT02415413
- Testing
- carfilzomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in Spain
- Volunteers
- 90 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Smoldering Multiple Myeloma
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or…
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Trial name
- NCT06768489
- Testing
- JNJ-79635322, Daratumumab, Pomalidomide
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Background: Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection.
- Trial name
- NCT01572480
- Testing
- Carfilzomib, Revlimid, Dexamethasone
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
This is a randomized, 2-arm phase II, placebo-controlled, multi-center study, where the investigators aim to evaluate whether the reported benefits of denosumab, delay of SRE and decrease in myeloma growth promotion, reduce the…
- Trial name
- DEFENCE (NCT03792763)
- Testing
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
High Risk Smoldering Multiple Myeloma
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.
- Trial name
- NCT06745687
- Testing
- CM336
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Smoldering Multiple Myeloma
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical…
- Trial name
- NCT05597345
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
High-risk Smoldering Multiple Myeloma, Multiple Myeloma
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and…
- Trial name
- PRISM (NCT04775550)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Omar Nadeem, MD
Smouldering Myeloma
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg…
- Trial name
- HO147SMM (NCT03673826)
- Testing
- Carfilzomib, Dexamethasone, Lenalidomide
- Where
- 16 sites in Czechia, Italy and 2 more
- Volunteers
- 58 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Smoldering Plasma Cell Myeloma
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
- Trial name
- NCT02960555
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Smouldering Myeloma
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.
- Trial name
- MODIFY (NCT06762769)
- Testing
- Isatuximab, Iberdomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM.
- Trial name
- ERASMM (NCT06183489)
- Testing
- Elranatamab
- Where
- 18 sites in France, Italy and 2 more
- Volunteers
- 50 people
- Sponsor
- European Myeloma Network B.V.
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma.
- Trial name
- NCT01169337
- Testing
- Clinical Observation, Lenalidomide, Quality-of-Life Assessment
- Where
- 605 sites in United States, Ireland and 1 more
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Smoldering Multiple Myeloma
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.
- Trial name
- NCT03850522
- Testing
- PD-L1 peptide
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Lene Meldgaard Knudsen